アフリベルセプトの中国市場（2022年～2031年）

2018年にアフリベルセプトが中国市場に参入して以来、中国のアフリベルセプトの売上高は2018年に830万人民元となり、2018年～2021年の間にCAGR206%で成長し、2021年には2億3800万人民元に達しました。2021年はCOVID-19の流行によりCAGR116%と成長が鈍化しましたが、流行状況が改善され、2023年～2026年にかけては回復成長すると予測されています。

2022年7月時点では、Bayer AGは中国のアフリベルセプト市場における唯一のメーカーです。しかし、中国では多くの製薬会社がアフリベルセプトのジェネリック化を進めており、今後5年以内に後発品が中国市場に参入すると予測されていますが、短期的にはバイエルの先発品に大きな影響を与えることはないと考えられます。

当レポートでは、中国のアフリベルセプトについて調査分析し、市場規模、メーカー分析、市場予測などを提供しています。

第1章 アフリベルセプトの関連概念

• アフリベルセプトの適応症
• 中国におけるアフリベルセプトの開発
• 中国におけるアフリベルセプトの政府承認
• 中国におけるアフリベルセプトの販売に対するCOVID-19の影響

第2章 中国のアフリベルセプトの販売（2018年～2021年）

• アフリベルセプトの売上高
  • 全体の売上高
  • 地域別の売上高
• アフリベルセプトの販売数量
  • 全体の販売数量
  • 地域別の販売数量
• 中国のアフリベルセプトの販売：投与方法別（2018年～2021年）
  • 眼内注射
  • その他の投与方法の分析

第3章 中国の主要アフリベルセプトメーカーの分析（2018年～2021年）

• 主要アフリベルセプトメーカーの市場シェア分析
  • 市場シェア調査：売上高別
  • 市場シェア調査：販売数量別
• Bayer AG
  • 企業プロファイル
  • 中国でのEYLEA（Bayer社アフリベルセプト）の販売

第4章 中国のさまざまなメーカーのアフリベルセプト価格（2021年～2022年）

• Bayer AG（EYLEA）
• その他

第5章 中国のアフリベルセプト薬市場の見通し(2022年～2031年）

• 中国のアフリベルセプト市場開発の影響因子
  • 中国のアフリベルセプト市場に対するCOVID-19の影響
  • 市場促進要因と機会
  • 市場の脅威と課題
• 市場規模の予測
• 市場動向の予測

List of Charts

• Chart Aflibercept Drugs Approved by Chinese Government, by 2022
• Chart Sales Value of Aflibercept in China, 2018-2021
• Chart Sales Value of Aflibercept in Regions of China, 2018-2021 (Unit: CNY thousand)
• Chart Sales Volume of Aflibercept in China, 2018-2021
• Chart Sales Volume of Aflibercept in Regions of China,2018-2021
• Chart Sales value and volume of aflibercept intravitreal injection in China 2018-2021
• Chart Market Share of Aflibercept Manufacturers by Sales Value in China, 2018-2021
• Chart Market Share of Aflibercept Manufacturers by Sales Volume in China, 2018-2021
• Chart Profile of Bayer AG
• Chart Sales Value of Bayer AG's Aflibercept in China, 2018-2021
• Chart Sales Volume of Bayer AG 's Aflibercept in China, 2018-2021
• Chart EYLEA sold in the Chinese market
• Chart Prices of BAYER AG's Aflibercept (EYLEA ®) in Parts of China, 2021
• Chart Forecast on sales of aflibercept in China 2022-2026

Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer. Regeneron has exclusive sales rights in the U.S. market, while Bayer obtains exclusive sales rights outside the U.S. Their Aflibercept, EYLEA was launched in China in 2018. By July 2022, Bayer AG is the only manufacturer in the Chinese Aflibercept market.

According to CRI's market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY238 million in 2021. The annual growth rate in 2021 was 116%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of aflibercept in China is 206% from 2018 to 2021.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Aflibercept will have a recovery growth from 2023 to 2026. In addition, the sales will also increase due to market expansion. Currently, China has only approved two indications for Aflibercept, including treatment of wAMD and treatment of DME. However, Aflibercept had five approved indications globally, which means the sales will continue to grow as the number of indications expands. On the other hand, though the anti-VEGF ophthalmic drug market where Aflibercept belongs to accounts for the largest market share in the ophthalmology drug industry, the penetration rate for the anti-VEGF drug is still low. The penetration rate for the anti-VEGF drug is about 1% in China, while it exceeds 5% in the U.S. Since the market demand has not yet reached saturation, the sales will keep increasing. Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.

Qilu Pharmaceutical, a local Chinese pharmaceutical company, received CDE (CENTER FOR DRUG EVALUATION, NMPA) approval for its marketing authorization application for aflibercept intravitreal injection in April 2022, which is the first biosimilar application for aflibercept in China.

According to CRI's market research, a number of other pharmaceutical companies in China are in the process of genericizing aflibercept, such as Clover Biopharmaceuticals' aflibercept intraocular injection, which is in the clinical phase of application, and Shandong Boan Biotechnology Co.

It is expected that the generic version of aflibercept will enter the Chinese market in the next five years, but it is unlikely to have a significant impact on Bayer's original drug in the short term.

Topics covered:

• The impact of COVID-19 on China's aflibercept market

• Sales value and volume of China's aflibercept 2016-2020

• Competitive landscape of China's aflibercept market

• Prices of aflibercept in China

• Prices of aflibercept in China by regions and manufacturers

• Analysis on factors affecting the development of China's aflibercept market

• Prospect of China's aflibercept market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Aflibercept

• 1.1 Indications for Aflibercept
• 1.2 Development of Aflibercept in China
• 1.3 Governmental Approval of Aflibercept in China
• 1.4 The Impact of COVID-19 on Aflibercept sales in China

2 Sales of Aflibercept in China, 2018-2021

• 2.1 Sales Value of Aflibercept
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
• 2.2 Sales Volume of Aflibercept
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Region
• 2.3 Sales of Aflibercept by Dosage Form in China, 2018-2021
  • 2.3.1 Intraocular Injection
  • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Aflibercept Manufacturers in China, 2018-2021

• 3.1 Analysis of Market Share of Major Aflibercept Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
• 3.2 Bayer AG
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of EYLEA (Bayer's Aflibercept) in China

4 Prices of Aflibercept for Different Manufacturers in China, 2021-2022

• 4.1 Bayer AG (EYLEA)
• 4.2 Others

5 Prospect of Chinese Aflibercept drug Market, 2022-2031

• 5.1 Influential Factors of Chinese Aflibercept Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Aflibercept Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
• 5.2 Forecast on Market Size
• 5.3 Forecast on Market Trend